---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-26-038095"
form_type: "8-K"
ticker: "PHGE"
cik: "0001739174"
company_name: "BiomX Inc."
filed_at: "2026-04-01T23:59:59+00:00"
generated_at: "2026-05-15T07:59:35.057616+00:00"
event_type: "m_and_a"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# BiomX secures option to buy defense-tech DFSL; $5M convertible note plus equity stakes up to 19.99%

## Summary
- Option to purchase 100% of Mandragola's DFSL shares; exercise after Mandragola acquires 60% of DFSL.
- Consideration: $100K cash, $5M convertible note, preferred stock for 9.9% of common, pre-funded and 5-year warrants at $12 exercise for up to 19.99%.
- Closing subject to Israel Innovation Authority approval of DFSL ownership transfer and standard conditions.
- If DFSL annual revenue reaches $25M+ from FY2027, Mandragola receives 5% revenue bonus in cash or restricted stock.
- BiomX will seek shareholder approval for issuance of >19.99% of common on conversion/exercise; proxy statement to be filed.

## SEC filing metadata
- accession: 0001213900-26-038095
- form_type: 8-K
- ticker: PHGE
- cik: 0001739174
- company_name: BiomX Inc.
- filed_at: 2026-04-01T23:59:59+00:00
- event_type: m_and_a
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1739174/000121390026038095/0001213900-26-038095-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1739174/000121390026038095/ea0284436-8k_biomx.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-26-038095
- JSON: https://secwatch.observer/filing/0001213900-26-038095.json
- Plain text: https://secwatch.observer/filing/0001213900-26-038095.txt

## Source-grounded claims
- claim_id: 8d1762da7a9f79bcbe05730cebf89d6acf5cd7fc
  claim: BiomX Inc. entered into Option and Undertaking Agreement with Mandragola Ltd (effective 2026-03-31).
  evidence_excerpt: On March 31, 2026, BiomX Inc., a Delaware corporation (“BiomX” or the “Company”)) and Mandragola Ltd, a company formed under the laws of the State of Israel (“Mandragola), entered into an Option and Undertaking Agreement (the “Option Agreement”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1739174/000121390026038095/0001213900-26-038095-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.